Post-earnings recap
Reported
Tue, Mar 24, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
IDEAYA Biosciences reported a loss per share of $0.53, but the stock rose nearly 12% following the earnings release. Investors may be reacting positively to the company's ongoing clinical programs despite the lack of revenue details and guidance. The stock movement suggests confidence in the company's future potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.53 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized ongoing efforts in their clinical development. There was no specific guidance provided for future performance.
Management did not provide specific revenue figures or guidance for the upcoming period.
The focus remains on advancing their clinical programs.